021-51111890
购物车（）
sales@molnova.cn
Roslin 2 bromide
CAS No. 29574-21-8
Roslin 2 bromide ( Benzylhexamethylenetetramine bromide )
产品货号. M27793 CAS No. 29574-21-8
Roslin 2 bromide 是一种 p53 重激活剂，可破坏 FAK 的结合，p5Roslin 2 bromide 具有抗癌作用。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥809 | 有现货 |
|
| 10MG | ￥1188 | 有现货 |
|
| 25MG | ￥1981 | 有现货 |
|
| 50MG | ￥2762 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ￥832 | 有现货 |
|
生物学信息
-
产品名称Roslin 2 bromide
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Roslin 2 bromide 是一种 p53 重激活剂，可破坏 FAK 的结合，p5Roslin 2 bromide 具有抗癌作用。
-
产品描述Roslin 2 bromide is a p53 reactivator that disrupts the binding of FAK and p5Roslin 2 bromide exhibits anticancer effects.(In Vitro):Roslin 2 bromide decreases cancer cell viability and clonogenicity in a p53-dependent manner.(In Vivo):Roslin 2 bromide (60 mg/kg; i.p) significantly decreased tumor growth, disrupts the complex of FAK and p53, and up-regulated p21 in HCT116 p53+/+ but not in HCT116 p53-/- xenografts.
-
体外实验Roslin 2 bromide decreases cancer cell viability and clonogenicity in a p53-dependent manner. Roslin 2 bromide increases p53 transcriptional activity that is inhibited by FAK using p21, Mdm-2, and Bax-promoter targets. Roslin 2 bromide also causes increased expression of p53 targets: p21, Mdm-2 and Bax proteins.
-
体内实验Roslin 2 (60 mg/kg; i.p; 5 days/week) bromide significantly decreases tumor growth, disrupts the complex of FAK and p53, and up-regulates p21 in HCT116 p53+/+ but not in HCT116 p53-/- xenografts in vivo.
-
同义词Benzylhexamethylenetetramine bromide
-
通路Angiogenesis
-
靶点FAK
-
受体Human Endogenous Metabolite|Drug Metabolite|Parasite|Purine nucleoside phosphorylase
-
研究领域——
-
适应症——
化学信息
-
CAS Number29574-21-8
-
分子量311.227
-
分子式C13H19BrN4
-
纯度>98% (HPLC)
-
溶解度——
-
SMILES[Br-].C(c1ccccc1)[N+]12CN3CN(CN(C3)C1)C2
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Pacher P, et al. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006 Mar;58(1):87-114.
